TN-002

TN-002 is a small molecule 5-HT2A antagonist being developed by Transneural Therapeutics for the treatment of migraine and chronic pain. Transneural Therapeutics, a biotechnology company that emerged from stealth in April 2025 as a spin-out of CaaMTech, focuses on developing novel neuroplastogens and serotonergic therapeutics for neuropsychiatric and neurodegenerative diseases. TN-002 is currently in the preclinical stage of development, specifically at the candidate selection phase. The drug's mechanism of action involves the antagonism of the 5-HT2A receptor, which is a validated target for modulating pain signaling and vascular responses associated with migraines. While the company's lead asset, TN-001, is a dual 5-HT2A partial agonist/5-HT2C antagonist for depression and PTSD, TN-002 represents a distinct program specifically positioned for pain management.